Rize Oncology Inc. (CSE:RIZE)
Canada · Delayed Price · Currency is CAD 0.0300
-0.0200 (-40.00%)
Inactive · Last trade price on May 23, 2025
Rize Oncology Company Description
Rize Oncology Inc. engages in the development of oncology therapeutics.
It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025.
Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.
Rize Oncology Inc.
| Country | Canada |
| Founded | 2018 |
| Industry | Pharmaceutical Preparations |
| CEO | Roland Boivin |
Contact Details
Address: 301 – 1665 Ellis Street Kelowna, British Columbia V1Y 2B3 Canada | |
| Phone | 514-796-2640 |
| Website | rizeoncology.com |
Stock Details
| Ticker Symbol | RIZE |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Roland Boivin | Chief Executive Officer |
| Jim O'Neill | Chief Financial Officer |